Opthea Limited (AU:OPT) has released an update.
Opthea Limited has announced the appointment of Sujal Shah, the former CEO of CymaBay Therapeutics, to their Board of Directors and as the new Chair of the Audit and Risk Committee, effective April 4, 2024. Shah’s extensive experience in biopharmaceuticals and successful capital formation at CymaBay, which was recently acquired for $4.3 billion, is expected to bolster Opthea’s strategic growth as they progress with their lead product candidate for treating retinal diseases. This leadership change coincides with the resignation of Daniel Spiegelman from the board.
For further insights into AU:OPT stock, check out TipRanks’ Stock Analysis page.
